NASDAQ:SGMT Sagimet Biosciences (SGMT) Stock Price, News & Analysis $1.90 -0.04 (-2.06%) Closing price 04:00 PM EasternExtended Trading$1.90 0.00 (0.00%) As of 04:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Sagimet Biosciences Stock (NASDAQ:SGMT) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Sagimet Biosciences alerts:Sign Up Key Stats Today's Range$1.90▼$2.1250-Day Range$1.94▼$5.1352-Week Range$1.73▼$7.38Volume682,572 shsAverage Volume844,172 shsMarket Capitalization$58.28 millionP/E RatioN/ADividend YieldN/APrice Target$22.40Consensus RatingModerate Buy Company OverviewSagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic pathways in the United States. The company's lead drug candidate is Denifanstat, a once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction associated steatohepatitis. It also develops TVB-3567, a FASN inhibitor for the treatment of acne; and other oncology programs. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.Read More… Remove Ads Sagimet Biosciences Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks52nd Percentile Overall ScoreSGMT MarketRank™: Sagimet Biosciences scored higher than 52% of companies evaluated by MarketBeat, and ranked 453rd out of 904 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.4 / 5Analyst RatingModerate Buy Consensus RatingSagimet Biosciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 4 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageSagimet Biosciences has only been the subject of 1 research reports in the past 90 days.Read more about Sagimet Biosciences' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Sagimet Biosciences are expected to decrease in the coming year, from ($1.60) to ($4.03) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Sagimet Biosciences is -1.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Sagimet Biosciences is -1.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSagimet Biosciences has a P/B Ratio of 0.48. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Sagimet Biosciences' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted18.01% of the float of Sagimet Biosciences has been sold short.Short Interest Ratio / Days to CoverSagimet Biosciences has a short interest ratio ("days to cover") of 5.1.Change versus previous monthShort interest in Sagimet Biosciences has recently decreased by 15.86%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldSagimet Biosciences does not currently pay a dividend.Dividend GrowthSagimet Biosciences does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted18.01% of the float of Sagimet Biosciences has been sold short.Short Interest Ratio / Days to CoverSagimet Biosciences has a short interest ratio ("days to cover") of 5.1.Change versus previous monthShort interest in Sagimet Biosciences has recently decreased by 15.86%, indicating that investor sentiment is improving significantly. News and Social Media2.8 / 5News Sentiment0.97 News SentimentSagimet Biosciences has a news sentiment score of 0.97. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.63 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Sagimet Biosciences this week, compared to 2 articles on an average week.Search InterestOnly 6 people have searched for SGMT on MarketBeat in the last 30 days. This is a decrease of -63% compared to the previous 30 days.MarketBeat Follows3 people have added Sagimet Biosciences to their MarketBeat watchlist in the last 30 days. Company Ownership2.5 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Sagimet Biosciences insiders have not sold or bought any company stock.Percentage Held by Insiders17.60% of the stock of Sagimet Biosciences is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions87.86% of the stock of Sagimet Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Sagimet Biosciences' insider trading history. Receive SGMT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Sagimet Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address SGMT Stock News HeadlinesSagimet Biosciences Gets Clearance To Initiate Phase 1 Study Of TVB-3567 For Treatment Of AcneMarch 13, 2025 | nasdaq.comSagimet Biosciences Inc.: Sagimet Biosciences Announces Clearance of IND for FASN Inhibitor TVB-3567, to be Developed for the Treatment of AcneMarch 12, 2025 | finanznachrichten.deDOGE Social Security bombshell?Elon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social Security, finding what he says is widespread fraud across the agency.April 8, 2025 | Altimetry (Ad)Sagimet Biosciences reports Q4 EPS (50c), consensus (63c)March 12, 2025 | markets.businessinsider.comSagimet Biosciences Reports Full Year 2024 Financial Results and Provides Corporate UpdatesMarch 12, 2025 | globenewswire.comSagimet Biosciences announces clearance of IND for FASN inhibitor TVB-3567March 11, 2025 | markets.businessinsider.comSagimet Biosciences Announces Clearance of IND for FASN Inhibitor TVB-3567, to be Developed for the Treatment of AcneMarch 11, 2025 | globenewswire.comSagimet Biosciences' Denifanstat Should Be Worth More TodayMarch 7, 2025 | seekingalpha.comSee More Headlines SGMT Stock Analysis - Frequently Asked Questions How have SGMT shares performed this year? Sagimet Biosciences' stock was trading at $4.50 on January 1st, 2025. Since then, SGMT stock has decreased by 57.8% and is now trading at $1.90. View the best growth stocks for 2025 here. How were Sagimet Biosciences' earnings last quarter? Sagimet Biosciences Inc. (NASDAQ:SGMT) announced its earnings results on Wednesday, March, 12th. The company reported ($0.50) EPS for the quarter, beating analysts' consensus estimates of ($0.65) by $0.15. When did Sagimet Biosciences IPO? Sagimet Biosciences (SGMT) raised $85 million in an IPO on Friday, July 14th 2023. The company issued 5,312,500 shares at $16.00 per share. How do I buy shares of Sagimet Biosciences? Shares of SGMT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Sagimet Biosciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Sagimet Biosciences investors own include XPeng (XPEV), Iovance Biotherapeutics (IOVA), Taiwan Semiconductor Manufacturing (TSM), Avino Silver & Gold Mines (ASM), Avino Silver & Gold Mines (ASM) and Tenet Healthcare (THC). Company Calendar Last Earnings3/12/2025Today4/08/2025Next Earnings (Estimated)5/21/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:SGMT CIK1400118 Websagimet.com Phone650-561-8600FaxN/AEmployees8Year FoundedN/APrice Target and Rating Average Stock Price Target$22.40 High Stock Price Target$32.00 Low Stock Price Target$6.00 Potential Upside/Downside+1,054.6%Consensus RatingModerate Buy Rating Score (0-4)2.80 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($1.43) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-27,880,000.00 Net MarginsN/A Pretax Margin-1,462.75% Return on Equity-23.63% Return on Assets-22.91% Debt Debt-to-Equity RatioN/A Current Ratio38.41 Quick Ratio38.41 Sales & Book Value Annual Sales$2 million Price / Sales29.75 Cash FlowN/A Price / Cash FlowN/A Book Value$3.98 per share Price / Book0.49Miscellaneous Outstanding Shares30,675,000Free Float25,276,000Market Cap$59.51 million OptionableOptionable Beta2.40 These 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (NASDAQ:SGMT) was last updated on 4/8/2025 by MarketBeat.com Staff From Our PartnersFeds Just Admitted It—They Can Take Your CashThe Government Just Said Your Money Isn't Yours That's right—According to the DOJ, YOUR hard-earned money i...Priority Gold | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsMusk confirmed that SpaceX's Starship will carry Optimus to Mars in 2026 as part of an autonomous mission to h...InvestorPlace | Sponsored**Breaking NEWS* This Company Starts To Rally As it Reduces $20 Million in Debt**Breaking NEWS* This Company Starts To Rally As it Reduces $20 Million in Debt Discover why Notable Names ...Huge Alerts | SponsoredTrump’s betrayal exposed Fair warning: this will not make for easy viewing. Especially if you voted for Trump, put your faith in hi...Porter & Company | SponsoredTrump’s Secret WeaponHave you looked at the stock market recently? Millions of investors are scrambling trying to figure out what's...American Alternative | SponsoredGold Hits $3,000… Here’s How You Can Get More for Under $20With gold surging to record highs, currently trading above $3,000 an ounce, and central banks aggressively sto...The Oxford Club | SponsoredFBI Warns: Wave Of Retiree Cyber Hacks Coming In 2025Try to think back to the fall of 2008… The pandemic accelerated America's descent into a “no-cash society” ...Colonial Metals | SponsoredElon’s ‘Strike Squad’ sends these 9 stocks soaring?Elon Musk's DOGE 'strike squad' just revealed it's speeding up the rollout of a radical technology across the ...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sagimet Biosciences Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sagimet Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.